Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Holger Eidtmann
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
New England Journal of Medicine
Medicine
Clinical Response After Two Cycles Compared to HER2, Ki-67, P53, and BCL-2 in Independently Predicting a Pathological Complete Response After Preoperative Chemotherapy in Patients With Operable Carcinoma of the Breast
Breast Cancer Research
Cancer Research
Oncology
Related publications
Predicting Successful Conservative Surgery After Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer
Journal of Breast Disease
Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer
Journal of Cancer Research and Clinical Oncology
Medicine
Cancer Research
Oncology
Cost-Effectiveness Analysis of Neoadjuvant Chemotherapy With Zoledronic Acid for HER2-Negative Breast Cancer in Japan: The JONIE1 Study
Health
Comparative Analysis of Different Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer
Tumors of female reproductive system
Neoadjuvant Chemotherapy in Breast Cancer
Current Neoadjuvant Treatment Options for HER2 Positive Breast Cancer
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
Neoadjuvant Chemotherapy: Role in Breast Cancer
Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer
Oncotarget
Oncology
Neoadjuvant Chemotherapy for Early Breast Cancer – Author's Reply
The Lancet Oncology
Oncology
